JPWO2010041647A1 - Endurance improver, fatigue inhibitor, or fatigue recovery agent comprising an amino acid composition as an active ingredient - Google Patents

Abstract

This invention makes it a subject to aim at reduction of the component of an amino acid with low solubility while trying to specify the component and density | concentration of an amino acid effective in endurance improvement, fatigue prevention, or fatigue recovery from an amino acid composition. The present inventors identified for the first time that the amino acid that contributes to improving endurance is tyrosine, and after examining the concentration necessary for improving endurance for tyrosine with low solubility in water, the solubility is high, The present inventors have found an amino acid composition excellent in improving endurance.

Description

  The present invention belongs to the technical field of compositions for improving endurance, preventing fatigue, or recovering from fatigue. More specifically, the present invention relates to an amino acid composition that improves endurance, prevents fatigue, or recovers fatigue.

  Lifestyle-related diseases such as diabetes cause arteriosclerosis, etc. With the aging of the population, overcoming prevention of lifestyle-related diseases has become an important issue. For example, it is said that the reserve army for these lifestyle-related diseases is 20 million in Japan alone. Therefore, as a countermeasure for lifestyle-related diseases, medical examinations and health guidance using the concept of metabolic syndrome have been performed. And exercise is effective in preventing this metabolic syndrome, and improvement in endurance is a major point.

  In addition, in order to improve endurance, attempts have been made not only by exercise training but also by ingestion of foods, supplements, and medicines containing other active ingredients. For example, malic acid and citric acid are said to have an endurance enhancing effect (Non-patent Document 1). Furthermore, it is reported that a protein having a specific molecular weight (57 KDa) isolated from royal jelly has an aerobic exercise promoting component effective for improving cardiopulmonary function and endurance (Patent Document 1).

  Further, cacao nibs and / or processed products thereof (Patent Document 2), food compositions containing Coenzyme Q10 and (-)-hydroxycitric acid (Patent Document 3), compositions containing thioctic acid or thioctic acid and creatine (Patent Documents) 4) is known as an active ingredient for improving endurance. And it is supposed that the composition containing panthetins and branched amino acids has an effect of preventing endurance reduction (Patent Document 5).

On the other hand, various actions have been known for amino acid compositions. A wasp-derived amino acid composition is used as a muscle strength-retaining agent, a nutritional tonic, an infusion solution, a nutritional supplement, a fatigue recovery agent, or a lactic acid production regulator (Patent Document 6). Furthermore, WO2003-011056 (Patent Document 7) describes a composition for recovering fatigue comprising aspartic acid as an active ingredient. JP 2008-105954 (Patent Document 8) describes an agent for promoting differentiation of bone marrow erythrocyte progenitor cells and an anemia treatment agent containing at least one of alanine, serine, glutamine, tyrosine and asparagine as an active ingredient. Has been. Japanese Patent Application Laid-Open No. 2008-081498 (Patent Document 9) describes a composition for suppressing fat accumulation containing threonine or leucine as an active ingredient.
JP 2001-172195 A JP 2006-282576 A JP 2004-81010 A JP 2007-131609 JP 2006-16358 Patent No.2518692 WO2003-011056 JP2008-105954 JP2008-081498 Journal of the Japan Society of Hemorheology, Vol. 6, No. 2 (2003) 83-88

  Various activities have been known in the past for amino acid compositions, but the optimal composition for improving endurance, preventing fatigue or recovering from fatigue has not been known yet, and for example, amino acid compositions derived from wasps It has not been specified which amino acid in the amino acid composition (mixture) is particularly effective for improving endurance and what concentration of amino acid is effective for improving endurance.

  In addition, amino acid compositions are often used, for example, as liquid beverages or liquids, but there are also components that can be dissolved in amino acid compositions due to differences in solubility for each amino acid. For example, since tyrosine has low solubility in water, it is desired to reduce its use amount as much as possible.

  Therefore, the present invention aims to identify amino acid components and concentrations effective for improving endurance, preventing fatigue, or recovering from fatigue in an amino acid composition, and reducing amino acid components with low solubility.

  The inventors of the present application have been studying various effects of amino acid compositions derived from wasps. By intensive research on the composition of amino acid composition, we first identified tyrosine as an amino acid that contributes to improving endurance, and further examined the concentration required for improving endurance for tyrosine with low water solubility. Later, an amino acid composition having high solubility and excellent endurance was found.

  This specification includes the contents described in the specification and / or drawings of Japanese Patent Application No. 2008-259678, which is the basis for the priority of the present application.

  For the first time, the present invention provides an amino acid component that improves endurance, prevents fatigue, or restores fatigue.

The change in body weight (Value are mean ± SE) during the experimental period is shown. There was no significant difference in the weight of each group. The effect on swimming time by single administration (Value are mean ± SE) is shown. The effect on swimming time by repeated administration (Value are mean ± SE) is shown. *: p <0.05, **: p <0.01 vs. control. The measured value of glucose in blood (Value are mean ± SE) is shown. The measured value of lactic acid (Value are mean ± SE) in blood is shown. *: p <0.05 vs. control. The measured value of free fatty acid (Value are mean ± SE) in blood is shown. ***: p <0.005 vs. control. The measured value of hydroxyl butyric acid (Value are mean ± SE) is shown. *: p <0.05 vs. control. The measured value of creatine kinase (Value are mean ± SE) is shown. The measured value of glycogen (Value are mean ± SE) of liver and muscle (hyfuku muscle) is shown. *: p <0.05 vs. control. The measured value of the fat tissue weight (Value are mean ± SE) around the testis is shown. **: p <0.01 vs. control. The measured values of gastrocnemius and quadriceps muscle weight (Value are mean ± SE) are shown. *: p <0.05 vs. control.

  All publications, patents and patent applications cited herein are incorporated herein by reference in their entirety.

1. Endurance improvement / fatigue prevention / fatigue recovery The present invention includes an amino acid composition for improving endurance and an endurance improver comprising the amino acid composition as an active ingredient. The amino acid composition for improving endurance of the present invention may be an edible, medical or health food amino acid composition. The endurance improver of the present invention is effective for improving both local endurance and systemic endurance.

In the measurement of endurance, for example, it can be measured by animal experiments using the method shown in the following examples. For example, in the measurement of whole body endurance, the expiration of the maximum oxygen uptake (VO ₂ max) It can also be measured by gas analysis. This can be measured by sampling directly from a moving subject via a gas mask.

  Furthermore, the present invention provides an amino acid composition that can be used as an anti-fatigue agent by taking (administering) in advance when it is desired to prevent fatigue, and by taking (administering) after the fact when fatigue is felt. Also included are amino acid compositions that can be used as fatigue recovery agents.

2. Endurance improving agent and amino acid composition having endurance improving action The present invention includes an endurance improving agent, an anti-fatigue agent, and a fatigue recovery agent characterized by containing at least tyrosine as an active ingredient. More specifically, the present invention relates to an endurance improver comprising only tyrosine, an anti-fatigue agent, and a fatigue recovery agent, and an endurance improvement agent containing an amino acid other than tyrosine, an anti-fatigue agent, and a fatigue recovery agent. Include. Examples of amino acids other than tyrosine include branched chain amino acids (BCAA), and specifically include the group consisting of valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine, and phenylalanine. Any one or more amino acids selected from

  More specifically, (1) as an amino acid composition, an amino acid composition comprising only tyrosine, valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine, and phenylalanine as an active ingredient, Strength improver, fatigue inhibitor, and / or fatigue recovery agent, and (2) tyrosine, valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine, phenylalanine, threonine, glycine, serine, methionine , Endurance improver, anti-fatigue agent, and / or fatigue recovery agent comprising an amino acid composition consisting of only histidine and tryptophan as an active ingredient.

  In the present invention, (3) 3-5 mol tyrosine, 4-8 mol valine, 2-12 mol leucine, 3-9 mol isoleucine, 0.1-5 mol arginine, 0.1-4 mol glutamic acid, As an active ingredient, an amino acid composition comprising aspartic acid 0.1 to 5 mol, alanine 0.1 to 12 mol, proline 4 to 30 mol, lysine 5 to 11 mol, and phenylalanine 0.5 to 5 mol, Endurance improver, fatigue inhibitor, and / or fatigue recovery agent, (4) 3-4 mol tyrosine, 4-8 mol valine, 2-12 mol leucine, 3-9 mol isoleucine, 0.1 0.1 arginine 5 mol, glutamic acid 0.1-4 mol, aspartic acid 0.1-5 mol, alanine 0.1-12 mol, proline 4-30 mol, lysine 5-11 mol, phenylalanine 0.5-5 , Threonine 2-15 mol, glycine 15-25 mol (or 20.5-25 mol), serine 0.1-5 mol, methionine 0.1-5 mol, histidine 0.1-5 mol, and tryptophan 0 It includes an endurance improver, an anti-fatigue agent, and / or a fatigue recovery agent containing an amino acid composition having a ratio of 1 to 5 mol as an active ingredient.

  And this invention includes (5) tyrosine 3.5-4 mol, valine 5-7 mol, leucine 6-8 mol, isoleucine 4-6 mol, arginine 3-5 mol, glutamic acid 3-5 mol, aspartic acid Endurance improver, fatigue comprising as an active ingredient an amino acid composition comprising 0.1 to 1 mol, alanine 6 to 8 mol, proline 15 to 20 mol, lysine 8 to 10 mol, and phenylalanine 3 to 5 mol Inhibitor and / or fatigue recovery agent, (6) tyrosine 3.8-4 mol, valine 5.8-6 mol, leucine 6.2-6.4 mol, isoleucine 4.5-4.7 mol , Arginine 3.5 to 3.7 mol, glutamic acid 3.2 to 3.4 mol, aspartic acid 0.15 to 0.17 mol, alanine 6.1 to 6.3 mol, proline 18 to 19 mol, lysine 8 .7-8 9 mol, phenylalanine 3.8-4 mol, threonine 7.2-7.4 mol, glycine 19-21 mol (or 20.5-21 mol), serine 2.5-2.7 mol, methionine 0.53 An endurance improver, an anti-fatigue agent, and / or an active ingredient comprising an amino acid composition comprising ˜0.55 mol, histidine 2.6 to 2.8 mol, and tryptophan 2.2 to 2.4 mol Or a fatigue recovery agent is also included.

  In this case, more specifically, the concentration of tyrosine is preferably 50 to 90%, more preferably 70 to 90%, still more preferably 75 to 85%, compared to the conventional amino acid composition (VAAM) derived from wasps. Particularly preferred is about 80%, and the tyrosine concentration is preferably 2.4 to 4.3 mol% (3.5 to 6.3 wt%), more preferably 3.3 to 4.3 mol% (4 .8 to 6.3 wt%), more preferably 3.6 to 4.1 mol% (5.2 to 5.9 wt%), and tyrosine is 0.05 to 0.065 mol. An aqueous solution contained in the aqueous solution in%.

  As a more preferred amino acid composition, tyrosine is about 3.9 mol (about 5.5 parts by weight), valine is about 6.0 mol (about 5.6 parts by weight), and leucine is about 6.3 mol (about 6 parts by weight). 0.5 parts by weight), about 4.6 moles (about 4.8 parts by weight) of isoleucine, about 3.6 moles (about 5.0 parts by weight) of arginine, and about 3.3 moles (about 3.8 parts) of glutamic acid. Parts by weight), about 0.16 moles (about 0.22 parts by weight) of aspartic acid, about 6.3 moles (about 4.4 parts by weight) of alanine, and about 18.4 moles (about 16.8 parts by weight) of proline. Part), about 8.8 moles (about 12.8 parts by weight) of lysine, about 3.9 moles (about 5.1 parts by weight) of phenylalanine, and about 7.3 moles (about 6.9 parts by weight) of threonine. Glycine about 19.5 mol (about 11.6 parts by weight), serine about 2.5 mol (about 2.1 parts by weight), methionine Amino acid composition comprising about 0.54 mole (about 0.64 parts by weight), histidine about 2.6 moles (about 3.2 parts by weight), and tryptophan about 2.2 moles (about 3.6 parts by weight) Things.

3. Form of use of endurance improver, fatigue inhibitor, and / or fatigue recovery agent of the present invention The use form of the endurance improver, fatigue inhibitor, or fatigue recovery agent of the present invention is not particularly limited, but for medical use Can also be used for food and drink and for nutritional supplements.

  In the case of medical use, it can be used by general administration routes such as oral administration, rectal administration, administration by injection or infusion. For oral administration, mix with the above composition itself or a pharmaceutically acceptable carrier, excipient, diluent, etc. to form powders, granules, tablets, capsules, troches, syrups, etc. You can also. In addition, for example, a suitable buffer, isotonic agent, etc. may be added as an injection and dissolved in sterilized distilled water.

  The endurance improver, fatigue inhibitor, or fatigue recovery agent of the present invention can be made into an appropriate dosage form such as a powder, granule, tablet, capsule, and liquid. For formulation, adjuvants commonly used in formulation, such as excipients, binders, disintegrants, and lubricants, can be added. Examples of excipients include starch, lactose, sucrose, methyl cellulose, carboxymethyl cellulose, sodium alginate, calcium hydrogen phosphate, synthetic aluminum silicate, microcrystalline cellulose, polyvinyl pyrrolidone (PVP), and hydroxypropyl starch (HPS). Examples of the binder include starch, microcrystalline cellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (PVP), gum arabic powder, gelatin, glucose, sucrose, and aqueous / ethanol solutions thereof. Examples of disintegrants include starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, microcrystalline cellulose, hydroxypropyl starch, and calcium phosphate. As lubricants, carnauba wax, light anhydrous silicic acid, synthetic aluminum silicate, natural aluminum silicate, synthetic magnesium silicate, hardened oil, hardened vegetable oil derivative (Sterotex HM), sesame oil, white beeswax, titanium oxide, dry hydroxide There are aluminum gel stearic acid, calcium stearate, magnesium stearate, talc, calcium hydrogen phosphate, sodium lauryl sulfate and the like.

  Since the endurance improver, fatigue inhibitor, or fatigue recovery agent containing the amino acid composition of the present invention is extremely safe, its dosage can be set very broadly. In general, it can be appropriately set in consideration of various factors such as the administration route and the age, weight, and symptoms of animals to be administered including humans. Although this invention is not limited to this, As an appropriate active ingredient, Preferably it is 0.3g-8g / kg / day, More preferably, it is 0.4g-5g / kg / day, More preferably, it is 0.5g-3g / kg / Day.

  In the endurance improver, anti-fatigue agent, or fatigue recovery agent of the present invention, a 0.3-6.0 wt% solution, preferably a 1.0-2.0 wt% solution, is added at 100-500 ml per day. It can be administered 1 to 3 times. In the case of injection, a solution of 0.3 to 6.0% by weight can be administered in an amount of 100 to 400 ml, preferably 150 to 300 ml per time. The endurance improver, fatigue inhibitor, or fatigue recovery agent of the present invention can be administered either orally or parenterally (intramuscular, subcutaneous, intravenous, suppository, transdermal, etc.).

  In the case of edible use, the endurance improver, fatigue inhibitor, or fatigue recovery agent of the present invention can be edible as it is, but can also be used as an additive to various foods. In addition, the amino acid composition of the present invention can be dissolved in water to make a beverage. In that case, other nutritional components such as water-soluble vitamins and taurine can be further added. And in order to improve palatability, it can also be set as a drink by adding salts, such as sodium chloride, acids (acidulant), such as a citric acid, and / or other suitable flavors. At this time, in order to improve stability, a pH adjuster and a chelating agent can be further added.

  The endurance improver, anti-fatigue agent, or fatigue recovery agent of the present invention is desirably administered continuously, and preferably administered for one week or longer.

  In the following examples, the following experimental samples were used.

(A) Experimental sample: The sample was suspended in distilled water and prepared as follows.

(1) DW (distilled water) = control
(2) Aqueous solution of amino acid composition derived from wasp (VAAM aqueous solution): 500 mg / kg. The composition is as follows.

  About 4.8 mol (about 6.9 parts by weight) of tyrosine, about 6.0 mol (about 5.6 parts by weight) of valine, about 6.3 mol (about 6.5 parts by weight) of leucine, and isoleucine About 4.6 mol (about 4.8 parts by weight), Arginine about 3.6 mol (about 5.0 parts by weight), Glutamic acid about 3.3 mol (about 3.8 parts by weight), Aspartic acid about 0.16 mol (about 0.22 parts by weight), alanine about 6.3 mol (about 4.4 parts by weight), proline about 18.4 mol (about 16.8 parts by weight), and lysine about 8. 8 moles (about 12.8 parts by weight), phenylalanine about 3.9 moles (about 5.1 parts by weight), threonine about 7.3 moles (about 6.9 parts by weight), and glycine about 19.5 moles (About 11.6 parts by weight), serine about 2.5 moles (about 2.1 parts by weight), methionine about 0.54 moles (about 0.64 parts by weight) , Histidine about 2.6 moles (about 3.2 parts by weight), and about 2.2 moles of tryptophan (about 3.6 parts by weight).

(3) An aqueous solution of an amino acid composition derived from a wasp with only tyrosine reduced to 80%: 500 mg / kg. In the following and the drawings, it may be marked as Tyr 80%.

(4) Aqueous solution of wasp-derived amino acid composition in which only tyrosine is reduced to 20%: 500 mg / kg. In the following and the drawings, it may be indicated as Tyr 20%.

 (B) The endurance test was performed by the method described in Jpn. J. Phys. Fitness Sports Med. 1995, 44: 225-238. In summary, after mice (10 per group) were fasted at room temperature for 16 hours, the amino acid composition was orally administered as a 1.8 wt% aqueous solution at 37.5 μl / g body weight and then at room temperature. I took a rest in 30 minutes. This is a flowing water pool (water is placed in a cylindrical water tank of 32 cm in diameter and 30 cm in depth and kept at 35 ° C., and a water flow at a speed of 8 m / min is created by a circulation device). A weight was attached to the tail of the mouse and allowed to swim, and the limit swimming time was measured.

(C) Experimental method: The following procedure was carried out.

(1) Four-week-old ddY male mice were divided into 4 groups after acclimation for 12 days using endurance evaluation as an index (grouping, 1 group: n = 10). In addition, this time is set to -1 week (-1 week). The change in body weight during the whole experiment is shown in FIG. There was no significant difference in the weight of each group.

  In the following endurance evaluations (2) to (4), a weight equivalent to 5% of the body weight was attached to the tail of the mouse, and the limit swimming time was measured.

(2) One week after swimming grouping, oral administration of the experimental sample was started, and swimming time was measured on the first day from the start of the administration (single administration test). This time is 0 week (0 week = 0 day). At this time, each group includes a control, an aqueous solution of an amino acid composition derived from a wasp (VAAM aqueous solution), an aqueous solution of an amino acid composition derived from an wasp obtained by reducing only tyrosine to 80% (Tyr 80%), or An aqueous solution (Tyr20%) of a wasp-derived amino acid composition in which only tyrosine was reduced to 20% was orally administered.

  The result is shown in FIG. As shown in FIG. 2, the swimming time was not prolonged by single administration.

(3) Thereafter, oral administration of the experimental sample was continued once a day for 7 weeks. Basically, during this period, a normal solid food (Lab MR Stock: Nippon Agricultural Industry) was freely ingested. However, in the swimming time measurement, blood collection, and dissection, the fasting was performed from the previous night (22:00).

(4) Measurement of swimming time was carried out every week up to 5 weeks (5th week). On the day of measurement of the swimming time, the experimental sample was orally administered 30 minutes before the start of swimming.

  The result is shown in FIG. In the tyrosine (Tyr) 100% group and the 80% group, the swimming time was significantly prolonged from the first week of administration compared to the control group. There was no difference between Tyr 100% group and 80% group. In the Tyr20% group, as compared with the control group, no increase in swimming time was observed even at the fifth week after the start of administration.

(5) At 6 weeks after the oral administration of the experimental sample, a weight equivalent to 5% of the body weight was attached to the tail of the mouse, allowed to swim for 15 minutes, blood was collected, blood sugar level, lactic acid in blood Value, blood free fatty acid (NEFA, Non-esterified fatty acid) value. Blood was also collected before administration and 30 minutes after administration (immediately before exercise) and measured in the same manner as described above. Glucose CII-Test Wako (manufactured by Wako Pure Chemical Industries) is used to measure blood glucose levels, Determiner LA (manufactured by Kyowa Medex) is used to measure lactic acid levels, and NEFA C-Test Wako (manufactured by Kyowa Medex Co., Ltd.). Wako Pure Chemical Industries, Ltd.) was used.

  The measurement result of the blood glucose level is shown in FIG. There was no significant difference in the blood glucose level of each group.

  The measurement result of the lactic acid level in blood is shown in FIG. Before administration and 30 minutes after administration (immediately before exercise), there was no significant difference in the lactic acid level in the blood of each group. Compared with the control group, the Tyr100% group and the Tyr80% group showed a significant decrease in lactic acid level immediately after exercise, and suppressed the increase in lactic acid associated with exercise.

  The measurement result of the free fatty acid (NEFA) value in blood is shown in FIG. In any of the Tyr 100% group, the Tyr 80% group, and the Tyr 20% group, a significant increase in free fatty acid (NEFA) value was observed immediately after exercise compared to the control group.

(6) Similarly, at 7 week (seventh week), blood was collected in the same manner, and a ketone (3-hydroxybutyric acid) value and a creatine kinase (CK) value were measured. Ketorex “Sanwa” (manufactured by Sanwa Chemical Co., Ltd.) was used for the measurement of ketone, and CPKII-Test Wako (manufactured by Wako Pure Chemical Industries, Ltd.) was used for the measurement of creatine kinase.

  The measurement result of ketone is shown in FIG. With exercise, hydroxylbutyric acid (ketone) levels generally increased, and in the Tyr 100% group and Tyr 80% group, a significant increase in ketone was observed immediately after exercise, compared with the control group.

  The measurement result of creatine kinase is shown in FIG. With exercise, creatine kinase (CK) levels generally increased, but there was no significant difference in the creatine kinase levels of each group.

 (7) Each group was divided into a non-exercise group and an exercise group (swimming) at 8 weeks (8th week) after the start of administration.

  Similarly, at 8 weeks, the mice were dissected and the organ weights (liver, kidney, spleen, peri-testicular fat, gastrocnemius, quadriceps) were measured. Glycogen levels were also measured in the liver and gastrocnemius muscle. Glucose CII-Test Wako (Wako Pure Chemical Industries, Ltd.) was used for glycogen measurement.

  In half of the mice, a weight equivalent to 5% of the body weight was attached to the tail and dissected immediately after swimming for 15 minutes (exercise group = with exercise). The other half of the mice were dissected without swimming (non-motor group = no exercise).

  The measurement result of the amount of glycogen is shown in FIG. In the non-exercise group (no exercise), there was no difference in liver and muscle glycogen levels in each group. On the other hand, in the exercise group (with exercise), the Tyr100% group and the 80% group showed significantly increased liver and muscle glycogen levels compared to the control group.

  Moreover, the measurement result of organ weight is shown to FIG. Around the testis, the Tyr 100% group showed a significant decrease in adipose tissue weight compared to the control group. In addition, the Tyr100% group significantly increased the weight of the typhoid muscle and quadriceps muscle compared with the control group. There were no differences in other organs (liver, kidney, spleen).

  INDUSTRIAL APPLICABILITY The present invention can be used as medicines, health and health foods, beverages, or feeds that are useful for improving endurance, recovering from fatigue, preventing fatigue, and the like for sports athletes, manual workers, livestock, and the like.

Claims (10)

  Endurance improver, fatigue inhibitor, or fatigue recovery agent containing tyrosine as an active ingredient.   Endurance improver, fatigue inhibitor, or fatigue recovery agent comprising an amino acid composition containing tyrosine as an active ingredient.   The endurance improver, fatigue inhibitor, or fatigue according to claim 2, wherein the amino acid composition containing tyrosine comprises only tyrosine, valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine, and phenylalanine. Recovery agent.   The amino acid composition containing tyrosine consists of only tyrosine, valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine, phenylalanine, threonine, glycine, serine, methionine, histidine, and tryptophan. Endurance improver, fatigue inhibitor, or fatigue recovery agent.   An amino acid composition containing tyrosine is 3-5 mol tyrosine, 4-8 mol valine, 2-12 mol leucine, 3-9 mol isoleucine, 0.1-5 mol arginine, 0.1-4 mol glutamic acid, aspartic acid The endurance improver and fatigue according to claim 3, comprising 0.1 to 5 mol, alanine 0.1 to 12 mol, proline 4 to 30 mol, lysine 5 to 11 mol, and phenylalanine 0.5 to 5 mol. An inhibitor or a fatigue recovery agent.   An amino acid composition containing tyrosine is 3-4 mol tyrosine, 4-8 mol valine, 2-12 mol leucine, 3-9 mol isoleucine, 0.1-5 mol arginine, 0.1-4 mol glutamic acid, aspartic acid 0.1-5 mol, alanine 0.1-12 mol, proline 4-30 mol, lysine 5-11 mol, phenylalanine 0.5-5 mol, threonine 2-15 mol, glycine 15-25 mol, serine 0. The endurance improver, anti-fatigue agent, or fatigue recovery according to claim 4, comprising 1 to 5 mol, methionine 0.1 to 5 mol, histidine 0.1 to 5 mol, and tryptophan 0.1 to 5 mol. Agent.   A tyrosine-containing amino acid composition comprises tyrosine 3.5 to 4 mol, valine 5 to 7 mol, leucine 6 to 8 mol, isoleucine 4 to 6 mol, arginine 3 to 5 mol, glutamic acid 3 to 5 mol, aspartic acid 0. 1-1 mol, alanine 6-8 mol, proline 15-20 mol, lysine 8-10 mol, phenylalanine 3-5 mol, threonine 7-9 mol, glycine 15-25 mol, serine 2-4 mol, methionine 0. The endurance improver, fatigue inhibitor, or fatigue recovery agent according to claim 4, comprising 5 to 1.5 mol, histidine 2 to 4 mol, and tryptophan 2 to 4 mol.   The amino acid composition containing tyrosine is 3.8-4 mol tyrosine, 5.8-6 mol valine, 6.2-6.4 mol leucine, 4.5-4.7 mol isoleucine, 3.5-3 arginine. 0.7 mol, glutamic acid 3.2-3.4 mol, aspartic acid 0.15-0.17 mol, alanine 6.1-6.3 mol, proline 18-19 mol, lysine 8.7-8.9 mol , Phenylalanine 3.8-4 mol, threonine 7.2-7.4 mol, glycine 19-21 mol, serine 2.5-2.7 mol, methionine 0.53-0.55 mol, histidine 2.6- The endurance improver, fatigue inhibitor, or fatigue recovery agent according to claim 4, comprising 2.8 moles and tryptophan 2.2 to 2.4 moles.   The endurance improver, fatigue inhibitor, or fatigue recovery agent according to any one of claims 1 to 8, wherein tyrosine is contained in the aqueous solution at 0.05 to 0.065 mol%.   The food / beverage products or food / beverage products for nutrition assistance containing the endurance improver, fatigue inhibitor, or fatigue recovery agent of any one of Claims 1-9.

Images